Adage Capital Partners Gp, L.L.C. Merus N.V. Transaction History
Adage Capital Partners Gp, L.L.C.
- $54.9 Billion
- Q4 2024
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Merus N.V. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 250,000 shares of MRUS stock, worth $11.2 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
250,000
Previous 185,000
35.14%
Holding current value
$11.2 Million
Previous $9.24 Million
13.74%
% of portfolio
0.02%
Previous 0.02%
Shares
6 transactions
Others Institutions Holding MRUS
# of Institutions
201Shares Held
57.2MCall Options Held
111KPut Options Held
85.7K-
Rtw Investments, LP New York, NY4.17MShares$186 Million2.86% of portfolio
-
Commodore Capital LP New York, NY3.87MShares$173 Million16.32% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY2.97MShares$133 Million3.1% of portfolio
-
Samlyn Capital, LLC New York, NY2.67MShares$119 Million1.81% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.13MShares$94.8 Million1.3% of portfolio
About Merus N.V.
- Ticker MRUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,878,200
- Market Cap $2.05B
- Description
- Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...